Back to top
more

Ikena Oncology (IKNA)

(Delayed Data from NSDQ)

$1.72 USD

1.72
41,732

+0.03 (1.78%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $1.72 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Best Momentum Stocks to Buy for July 12th

by Zacks Equity Research

IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.

New Strong Buy Stocks for July 12th

by Zacks Equity Research

USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024.

Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 8.33% and 44.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Shopify, Meta, Microsoft in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 15.22% and 8.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Ikena Oncology (IKNA) Might Surprise This Earnings Season

by Zacks Equity Research

Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why Momentum in Ikena Oncology, Inc. (IKNA) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ikena Oncology, Inc. (IKNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 26.09% and 13.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

by Zacks Equity Research

Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma are part of Zacks top Analyst Blog